Literature DB >> 22111037

The Association between Carotid Atherosclerosis and Glucose.

Bo Kyung Koo1.   

Abstract

Entities:  

Year:  2011        PMID: 22111037      PMCID: PMC3221021          DOI: 10.4093/dmj.2011.35.5.466

Source DB:  PubMed          Journal:  Diabetes Metab J        ISSN: 2233-6079            Impact factor:   5.376


× No keyword cloud information.
Carotid intimal-medial thickness (IMT) is used as a surrogate marker for atherosclerosis and can predict future clinical cardiovascular events such as myocardial infarction and ischemic stroke [1]. Furthermore, medications for prevention of cardiovascular events including lipid-lowering [2], anti-hypertensive [3], and anti-platelet drugs [4,5] can decrease carotid IMT, which implicates that carotid IMT can also be used to assess the efficacy of anti-atherosclerotic treatment. It is well documented that carotid IMT is markedly increased in subjects with high-cardiovascular disease risk such as those with diabetes [6], previous history of stroke [7] or myocardial infarction [8]. However, recent studies showed that subjects in the relatively low-risk group such as young subjects with obesity [9,10] or impaired glucose tolerance [11] also had increased carotid IMT compared to that of normal controls. In those low-risk subjects, glucose level significantly correlated with carotid IMT [10,12]. Non-diabetic subjects with parental history of diabetes or dyslipidemia also showed that disturbed carbohydrate metabolism is associated with carotid atherosclerosis [13,14]. In contrast, control of postprandial hyperglycemia by medication can regress carotid atherosclerosis [15]. Insulin resistance and inflammation might play an important role in the link between glucose abnormalities and carotid atherosclerosis [16,17]. Agewall et al. [18] showed a significant correlation between insulin sensitivity directly-assessed by clamp-study and carotid IMT in non-diabetic subjects. Inflammatory markers such as C-reactive protein [19,20] and TNF-α [21] are also significantly correlated with carotid IMT. History of gestational diabetes (GDM) is a risk factor of diabetes mellitus and is also characterized by insulin resistance [22,23]. Ku et al. [24] were unable to show a significant difference in carotid IMT according to history of GDM; however, they did show that glucose level in the postpartum period is significantly associated with carotid IMT in subjects with a previous history of GDM. This result shows agreement with previous studies focusing on other risk groups such as subjects with parental history of diabetes, obesity or dyslipidemia [13,14]. Considering the association between glucose abnormality and carotid atherosclerosis, screening and management of glucose abnormality in subjects with history of GDM is required. In addition, the significantly high risk of cardiovascular disease in subjects with history of GDM [22,23] calls for the concomitant management of other cardiovascular risk factors in such patients. However, considering cost, selection of a high risk group for future cardiovascular events might be required, and carotid IMT can provide such evidence. A prospective study to confirm the longitudinal association between glucose control and carotid IMT in subjects with a history of GDM and usefulness of carotid IMT is required.
  24 in total

Review 1.  Treatment of impaired glucose tolerance with acarbose and its effect on intima-media thickness: a substudy of the STOP-NIDDM trial (study to prevent non-insulin-dependent diabetes mellitus).

Authors:  Markolf Hanefeld
Journal:  Endocr Pract       Date:  2006 Jan-Feb       Impact factor: 3.443

Review 2.  Carotid artery intima-media thickness in patients with Type 2 diabetes mellitus and impaired glucose tolerance: a systematic review.

Authors:  G Brohall; A Odén; B Fagerberg
Journal:  Diabet Med       Date:  2006-06       Impact factor: 4.359

Review 3.  Statins: an essential component in the management of carotid artery disease.

Authors:  Kosmas I Paraskevas; George Hamilton; Dimitri P Mikhailidis
Journal:  J Vasc Surg       Date:  2007-08       Impact factor: 4.268

4.  Abdominal obesity is an independent risk factor for increased carotid intima- media thickness in obese children.

Authors:  Bülent Hacihamdioğlu; Vedat Okutan; Yilmaz Yozgat; Düzgün Yildirim; Murat Kocaoğlu; Mustafa Koray Lenk; Okan Ozcan
Journal:  Turk J Pediatr       Date:  2011 Jan-Feb       Impact factor: 0.552

5.  Insulin resistance, inflammation, and vascular disease in nondiabetic predialysis chronic kidney disease patients.

Authors:  Debasish Banerjee; Alejandro Recio-Mayoral; Nihil Chitalia; Juan-Carlos Kaski
Journal:  Clin Cardiol       Date:  2011-04-27       Impact factor: 2.882

6.  Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials.

Authors:  Ji-Guang Wang; Jan A Staessen; Yan Li; Luc M Van Bortel; Tim Nawrot; Robert Fagard; Franz H Messerli; Michel Safar
Journal:  Stroke       Date:  2006-06-08       Impact factor: 7.914

7.  Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus.

Authors:  C W Ahn; H C Lee; S W Park; Y D Song; K B Huh; S J Oh; Y S Kim; Y K Choi; J M Kim; T H Lee
Journal:  Diabetes Res Clin Pract       Date:  2001-04       Impact factor: 5.602

8.  Carotid artery wall intima-media thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk.

Authors:  S Agewall; B Fagerberg; S Attvall; I Wendelhag; V Urbanavicius; J Wikstrand
Journal:  Stroke       Date:  1995-06       Impact factor: 7.914

9.  Ultrasonographically assessed carotid morphology and the risk of coronary heart disease.

Authors:  J T Salonen; R Salonen
Journal:  Arterioscler Thromb       Date:  1991 Sep-Oct

10.  Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals.

Authors:  T Temelkova-Kurktschiev; C Koehler; F Schaper; E Henkel; A Hahnefeld; K Fuecker; G Siegert; M Hanefeld
Journal:  Diabetologia       Date:  1998-06       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.